News
Loss-of-function SCN2A mutations
The following work from Assistant Prof. Kevin Benders lab was presented on the 20th of October in Chicago, at Neuroscience 2019 held by Society for
© All rights reserved. SCN2A Australia | Privacy Policy
Resources
News
Natural History Study in SCN2A
The SCN2A International Natural History Study (NHS) is comprised of clinicians collaborating from multiple academic institutions, including US, European and Australian based clinicians. Dr. Katherine
News
The Florey Institute – SCN2A team
Today we are introducing the SCN2A research team at the Florey Institute. The team is lead by Prof Steven Petrou, Director of Florey Institute. The
News
Welcome to SCN2A Australia
Happy Australia Day! Today we launch SCN2A Australia. We look forward to working with families, researchers, clinicians and professional bodies to improve the lives of
Categories
Sign up to the newsletter for updates.
NEW YEAR - NEW LOOK![]()
![]()
We are currently booking in the first few episodes for 2022. ![]()
![]()
What OR who would you like to hear from in 2022??![]()
![]()
#SCN2A #CureSCN2A #scn2aawaress #scn2ainsights #scn2ascience #research #raredisease
SCN2A INSIGHTS: Computational analysis of 10,860 phenotypic annotations in individuals with SCN2A-related disorders![]()
![]()
Authors: Ingo Helbig et. al.![]()
![]()
Summary:![]()
For this study, the researchers collated data on 413 individuals with SCN2A-related disorders from publications on people with SCN2A between 2001 and 2019. For each of these individuals, details on clinical symptoms were coded in such a way that they could be digitised. This resulted in 10,860 symptoms across the 413 individuals. This data was then analysed using computer analysis to identify clusters of symptoms that mapped to distinct clinical presentations. ![]()
![]()
The authors grouped individuals in to 5 broad clinical categories (phenotypes): DEE, autism spectrum disorder, benign familial neonatal-infantile seizures, other epilepsies and atypical presentations. They then mapped the 5 most common symptoms associated with each clinical category (shown in the table). Then using these symptoms, they tested how accurately these symptoms were at predicting clinical presentations and variant function. This approach allowed correctly predicting gain of function versus loss of function variants in 84% of cases. ![]()
![]()
Outlining the common symptoms of the main clinical presentations of SCN2A, allows those managing people with SCN2A-related disorders to group patients in to particular sub-types. This is helpful, particularly with the development of precision-based treatments, which will benefit different sub-groups of people with SCN2A. However, this technique is not perfect, with only accurately classifying 84% of those with SCN2A-related disorders as gain versus loss of function. ![]()
![]()
This study shows the strength of adding computational analysis to the data collected clinically such as in natural history studies. It also highlights that each type of study is needed to get the best results. Careful and accurate clinical assessment, paired with strategies to digitise that data for computational analysis to find patterns over and above what can be recognised even by experienced clinicians.![]()
![]()
Follow the link for more information! scn2aaustralia.org/helbig-2021/![]()
![]()
#SCN2A #scn2ainsights #scn2asimplified #CureSCN2A